Hierarchical mesoporous silicon and albumin composite microparticles delivering DOX and FU for liver cancer treatment

被引:3
|
作者
Xu, Tianyuan [1 ,2 ,3 ,4 ,5 ]
Fan, Lu [4 ]
Wang, Li [4 ]
Ren, Haozhen [3 ]
Zhang, Qingfei [1 ,2 ,4 ,6 ]
Sun, Weijian [1 ,2 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Wenzhou 325027, Peoples R China
[2] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Peoples R China
[3] Nanjing Univ, Nanjing Drum Tower Hosp, Med Sch, Dept Hepatobiliary Surg, Nanjing 210008, Peoples R China
[4] Univ Chinese Acad Sci, Wenzhou Inst, Wenzhou 325001, Zhejiang, Peoples R China
[5] Guangxi Med Univ, Natl Ctr Int Res Biotargeting Theranost, Collaborat Innovat Ctr Targeting Tumor Diag & Ther, State Key Lab Targeting Oncol,Guangxi Key Lab Biot, Nanning 530021, Guangxi, Peoples R China
[6] Wenzhou Med Univ, Affiliated Hosp 2, Key Lab Pediat Hematol & Oncol Dis Wenzhou, Wenzhou 325027, Peoples R China
基金
中国国家自然科学基金;
关键词
Bovine serum albumin; Microfluidics; Microparticle; Liver cancer; Mesoporous silicon nanoparticle; DRUG-RELEASE; NANOPARTICLES; MICROFLUIDICS;
D O I
10.1016/j.ijbiomac.2024.131732
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Drug delivery systems based on hydrogel microcarriers have shown enormous achievements in tumor treatment. Current research direction mainly concentrated on the improvement of the structure and function of the microcarriers to effectively deliver drugs for enhanced cancer treatment with decreased general toxicity. Herein, we put forward novel hierarchical mesoporous silicon nanoparticles (MSNs) and bovine serum albumin (BSA) composite microparticles (MPMSNs@DOX/FU) delivering doxorubicin (DOX) and 5-fluorouracil (FU) for effective tumor therapy with good safety. The DOX and FU could be efficiently loaded in the MSNs, which were further encapsulated into methacrylate BSA (BSAMA) microparticles by applying a microfluidic technique. When transported to the tumor area, DOX and FU will be persistently released from the MPMSNs@DOX/FU and kept locally to lessen general toxicity. Based on these advantages, MPMSNs@DOX/FU could observably kill liver cancer cells in vitro, and evidently suppress the tumor development of liver cancer nude mice model in vivo. These results suggest that such hierarchical hydrogel microparticles are perfect candidates for liver cancer treatment, holding promising expectations for impactful cancer therapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Unique Advantages of Dendrimers-Structured Mesoporous Silica Nanoparticles over Traditional Hollow Ones in Delivering Bcl2-Functional Converting Peptide for Multidrug Resistant Cancer Treatment
    Wu, Yuehuang
    Ma, Fangmei
    Yu, Lixue
    Lin, Ruimiao
    Lin, Sijin
    Guo, Zhihan
    Zhou, Min
    Li, Mingyu
    Zhang, Yi
    Xie, Jingjing
    ADVANCED HEALTHCARE MATERIALS, 2024, 13 (23)
  • [32] Non-Pore Dependent and MMP-9 Responsive Gelatin/Silk Fibroin Composite Microparticles as Universal Delivery Platform for Inhaled Treatment of Lung Cancer
    Gou, Shuangquan
    Wang, Gangyang
    Zou, Yanan
    Geng, Wenbo
    He, Tingting
    Qin, Zizhen
    Che, Lingbin
    Feng, Qian
    Cai, Kaiyong
    ADVANCED MATERIALS, 2023, 35 (42)
  • [33] Preparation of magnetic and bioactive calcium zinc iron silicon oxide composite for hyperthermia treatment of bone cancer and repair of bone defects
    Jiang, Yumin
    Ou, Jun
    Zhang, Zhanhe
    Qin, Qing-Hua
    JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, 2011, 22 (03) : 721 - 729
  • [34] Preparation of magnetic and bioactive calcium zinc iron silicon oxide composite for hyperthermia treatment of bone cancer and repair of bone defects
    Yumin Jiang
    Jun Ou
    Zhanhe Zhang
    Qing-Hua Qin
    Journal of Materials Science: Materials in Medicine, 2011, 22 : 721 - 729
  • [35] Is the Technetium-99m Macroaggregated Albumin Scintigraphy a Certain Surrogate of 90Y-loaded Microspheres In the Treatment of Primary and Secondary Liver Cancer?
    De Teresa Herrera, R.
    Plaza De Las Heras, I.
    Field Galan, C.
    Seijas Marcos, S.
    Rodriguez Alfonso, B.
    Cardona Arbories, J.
    Mendez Alonso, S.
    Mitjavila Casanovas, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S799 - S800
  • [36] HIGH-DOSE 5-FLUOROURACIL (5-FU) AND FOLINIC ACID IN ADVANCED COLORECTAL SITES OF DISEASE CANCER RESISTANT TO STANDARD-DOSE LOCAL 5-FU TREATMENT - RESULTS OF A LIVER PHASE-II STUDY
    JAGER, E
    KLEIN, O
    WACHTER, B
    MULLER, B
    BRAUN, U
    KNUTH, A
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) : 1717 - 1717
  • [37] Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301)
    Ychou, M.
    Hohenberger, W.
    Thezenas, S.
    Navarro, M.
    Gascon, P.
    Bokemeyer, C.
    Shacham-Shmueli, E.
    Rivera, F.
    Choi, C. Kwok-Keung
    Santoro, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy
    Lim, L
    Gibbs, P
    Yip, D
    Shapiro, JD
    Dowling, R
    Smith, D
    Little, A
    Bailey, W
    Liechtenstein, M
    BMC CANCER, 2005, 5 (1)
  • [39] A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy
    L Lim
    P Gibbs
    D Yip
    JD Shapiro
    R Dowling
    D Smith
    A Little
    W Bailey
    M Liechtenstein
    BMC Cancer, 5
  • [40] EXPERIMENTAL STUDY ON ADRIAMYCIN ALBUMIN NANOPARTICLES GUIDED BY 131I-LABELLED ALPHA-FOETOPROTEIN MONOCLONAL ANTIBODY THROUGH RABBIT HEPATIC ARTERY IN THE TREATMENT OF LIVER CANCER
    YOU, X. I. A. N. G.
    LIN, Z. H. E. N. G. Y. U.
    CHEN, Y. I. P. I. N. G.
    CHEN, Z. H. O. N. G. W. U.
    CHEN, J. I. N.
    ACTA MEDICA MEDITERRANEA, 2022, 38 (02): : 879 - 883